FindTrial
Sign In

Cohort 3

DRUG7 trials

Sponsors

Protagonist Therapeutics Inc, Brown University, Cougar Biotechnology, Inc., Providence Health & Services, XOMA (US) LLC

Conditions

Anaplastic AstrocytomaAstrocytic TumorsB Cell LeukemiasB Cell LymphomasBrain TumorChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia ThalassemiaCongenital HyperinsulinismGlioblastoma Multiforme

Phase 1

A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema
CompletedNCT00439179
Brown UniversityMetastatic Pancreatic Cancer
Start: 2006-07-31End: 2007-12-31Updated: 2020-02-17
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CompletedNCT01400555
Cougar Biotechnology, Inc.Prostate Cancer, Prostate Neoplasms
Start: 2011-09-01End: 2017-02-28Updated: 2018-03-21
Phase I Study of Safety and Immunogenicity of ADU-623
CompletedNCT01967758
Providence Health & ServicesAnaplastic Astrocytoma, Astrocytic Tumors, Brain Tumor +1
Start: 2014-01-08End: 2018-08-15Updated: 2018-08-17
CD22 Redirected Autologous T Cells for ALL
Active, not recruitingNCT02650414
University of PennsylvaniaB Cell Leukemias, B Cell Lymphomas
Start: 2016-01-13End: 2037-12-01Target: 41Updated: 2026-07-07

Phase 2

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
CompletedNCT02604485
XOMA (US) LLCCongenital Hyperinsulinism
Start: 2015-10-31End: 2017-01-31Updated: 2017-02-06
A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) ß-Thalassemia Subjects with Chronic Anemia
Active, not recruitingLBCTR2019020179
Protagonist Therapeutics IncChronic anemia due to ineffective erythropoiesis (IE) in subjects with ß thalassemia Thalassemia
Start: 2019-03-11Target: 84Updated: 2026-02-02

Unknown Phase

Identification and Description of Patients With High-risk Non Metastatic RCC
RecruitingNCT07753343
University Hospital, BordeauxRenal Cell Carcinoma
Start: 2026-04-17End: 2028-04-17Target: 6109Updated: 2026-08-07

Related Papers

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Journal for ImmunoTherapy of Cancer2025-04-019 citations
Abstract B051: Marrow and peripheral blood cytokine architecture differences between pediatric patients receiving CD19- and CD22-directed CART
Cancer Research2024-09-05
IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22
Blood2023-11-02
CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
Blood2022-11-156 citations
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
2021-04-22148 citations
Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy
Blood2019-11-1317 citations
Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models
Blood2017-12-076 citations
Phase I study of safety and immunogenicity of ADU-623, a live-attenuated <i>Listeria monocytogenes </i>vaccine (Δ<i>actA</i>/Δ<i>inlB</i>) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas.
Journal of Clinical Oncology2015-05-201 citations
Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2014-05-202 citations
Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2014-02-011 citations